Name | Ezetimibe |
Synonyms | ZETIA Ezetimide Ezatimibe SCH 60969 Ezetimibe Ezetimibe-001 EzetimibeC24H21F2N03 Ticagrelor and its interMediate 1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one 1-(4-Flurophenyl)-(3R)-3-(4-flurophenyl)-(3S)-hydroxypropyl-(4S)-(4-hydroxyphenyl)-2-azetidinone (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Ezetimibe 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one (3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone, Sch-58235 |
CAS | 163222-33-1 |
EINECS | 682-606-0 |
InChI | InChI=1/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2 |
Molecular Formula | C24H21F2NO3 |
Molar Mass | 409.43 |
Density | 1.334±0.06 g/cm3(Predicted) |
Melting Point | 164-166°C |
Boling Point | 654.9±55.0 °C(Predicted) |
Specific Rotation(α) | D22 -33.9° (c = 3 in methanol) |
Flash Point | 349.9°C |
Solubility | Soluble in water (<1 mg/ml at 25 °C), alcohols, DMSO (82 mg/ml at 25 °C), ethanol (8 |
Vapor Presure | 4.83E-18mmHg at 25°C |
Appearance | powder |
Color | White or off-white |
pKa | 9.72±0.30(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
Refractive Index | 1.623 |
In vitro study | Ezetimibe significantly reduced total cholesterol, LDL cholesterol and triglycerides, and moderately increased high-density lipoprotein cholesterol. In Caco-2 cells, Ezetimibe reduced cholesterol transport by 31%, but did not affect yellow alcohol transport. Ezetimibe causes the surface receptor SR-BI,Niemann-Pick type C1 analog protein 1,ATP-binding cassette transporter, subfamily A(ABCA1) and the nuclear receptor retinoic acid receptor (RAR) gamma, the mRNA expression of sterol regulatory element binding proteins (SREBPs)-1 and -2, the beta subunit of Liver X receptor (LXR), is significantly reduced. |
In vivo study | In Western-style, low-fat, cholesterol-free mice, Ezetimibe reduced plasma cholesterol levels from 964 to 374 mg/dL, from 726 to 231 mg/dL, and from 516 to 178 mg/dL. Ezetimibe reduced the surface area of aortic atherosclerotic lesions from 20.2% in the control group to 4.1% in the Western diet group and 7.0% in the mice on the low fat cholesterol diet. Ezetimibe reduced the cross-sectional area of carotid atherosclerotic lesions by 97% in the Western and low-fat cholesterol diet groups and 91% in cholesterol-free mice. In Western, low-fat and cholesterol-free mice, Ezetimibe inhibited cholesterol absorption, decreased plasma cholesterol, increased high-density lipoprotein levels, and inhibited atherosclerosis. In preclinical animal models, Ezetimibe effectively inhibits cholesterol transport across the intestinal wall, thereby reducing plasma cholesteremia. In rats, Ezetimibe eliminates the pancreatic exocrine function of the intestine while maintaining bile flow. In cholesterol-fed hamsters, Ezetimibe reduced plasma cholesterol and liver cholesterol accumulation with an ED50 of 0.04 mg/kg. |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S24/25 - Avoid contact with skin and eyes. |
HS Code | 29337900 |